Antiviral Agents – Talk Bio

Merck to Acquire Cidara Therapeutics for $9.2 Billion

2 days ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy Designation, CD388, Cidara Therapeutics, Immunostimulating conjugate (antigen), influenza prevention, Merck

Merck; Cidara Therapeutics; acquisition; $9.2 billion; CD388; influenza prevention; antiviral; drug-Fc conjugate; Breakthrough Therapy Designation; Keytruda

Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push

4 weeks ago talkbio0Tagged Acquisition, Antiviral Agents, Breakthrough Therapy, CD388, Cidara Therapeutics, Influenza, J&J, Merck, Phase 3, sanofi, United States Food and Drug Administration

Merck; Cidara Therapeutics; CD388; antiviral; acquisition; influenza; phase 3; FDA Breakthrough Therapy; J&J; Sanofi; Keytruda

Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study

1 year ago talkbio0Tagged Antiviral Agents, Pediatric brand name, Phase 2 Clinical Trials, Respiratory syncytial virus, Zelicapavir

Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus

Johnson & Johnson Halts Phase II Dengue Study Amid Shift in R&D Priorities

1 year ago talkbio0Tagged Antiviral Agents, Communicable Diseases, Dengue Study, Johnson and Johnson, mosnodenvir, Phase II, Priorities, R&D

Johnson & Johnson, Dengue Study, Phase II, Antiviral Drug, Mosnodenvir, Infectious Diseases, R&D Priorities

Mpox Outbreak in Africa: Siga’s Tpoxx Antiviral Falls Short in Congo Study

1 year ago talkbio0Tagged 3-(2-methoxyphenyl)-5-methoxy-1,3,4-oxadiazol-2(3H)-one, Africa, Antiviral Agents, Clinical Research, Congo, Disease Outbreaks, Tpoxx

mpox, Tpoxx, antiviral, Congo study, Africa outbreak, Siga, tecovirimat